The interim report of an ongoing survey of CLL patients demonstrates that over 60% of respondents were unaware of different CLL risk groups and that about 20% felt they had "not received enough information about CLL to make informed treatment decisions". 14% of patients surveyed "were unable to obtain answers to their questions" about treatment decisions.
The global survey aims"to better understand what CLL patients know about their disease, their perspectives on diagnosis and treatment, and their unmet needs to ultimately improve their care and outcomes."
It shows why having a good relationship with your physician and participating in a forum like this one is so important but it also indicates a need for better patient education overall.
The interim report includes the responses of 118 patients from March to 1 July 2022 in Europe, Latin America, USA, and Turkey and is being presented at the upcoming ASH 2022 conference in December. The survey hopes to receive 1100 responses by the end of 2022.
The report concludes:
"The lack of awareness about risk groups and their treatment implications highlights an educational gap. Likewise, the preferences to receive oral treatments and participate in treatment decisions may point to unmet needs among CLL patients. These results indicate that most CLL patients are satisfied with the amount of information they receive from clinicians, but many awareness gaps suggest better patient education is needed." (my emphasis)
Further details:
"Almost three-quarters of respondents (74%) relied on their physicians to answer their questions about CLL and its treatment, but notably 10% used online sources or social media, and only 1% used educational materials or treatment centers. Most patients (88%) wanted to be involved in treatment decisions, but fewer participated in their treatment decisions (65%)."
As well as asking patients how they access information about CLL, it also asks questions about their understanding of their condition and their treatment preferences. So far, it has found that:
62% of patients were unaware or unsure of the existence of different CLL risk groups
63% reported a lack of awareness about laboratory tests to determine risk
67% reported a lack of awareness of the treatment implications of different risk levels
74% of respondents believed testing all patients to determine their risk is important
87% preferred oral medications but there was little difference in their preference for fixed duration (preferred by 54%) vs treatment until progression (preferred by 47%)
On the question of treatment side effects, the survey found that, while 91% discussed treatment side effects with their physicians, 42% were seeking additional information. "28% of patients indicated they would stop their treatment if they experienced unbearable side effects, and 12% had experienced such side effects. Among those that stopped treatment for these reasons, 76% believed their control of their CLL suffered. Notably, 92% of respondents were not worried about discussing side effects with their clinicians for fear of treatment discontinuation. Finally, 56% and 36% of respondents indicated treatment unavailability and financial issues had a high impact on treatment discontinuation."
The survey also examined the impact of COVID-19 on CLL patients:
95% of respondents received COVID-19 vaccination but "12% of respondents were unaware that CLL increased their vulnerability to infection"
"78% of respondents reported that their treatment was not negatively impacted by the pandemic"
3540 Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL - Constantine S. Tam et al